by admin | Sep 10, 2020 | Press Releases
MORRISTOWN, NJ, September 10, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will host one-on-one investor meetings during...
by admin | Sep 3, 2020 | Blog, Press Releases
MORRISTOWN, NJ, September 3, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – will present two posters with data on NTM-006, a new chemical entity (NCE) non-opioid, non-NSAID analgesic candidate that...
by admin | Jul 23, 2020 | Press Releases
Neumentum Provides Corporate Update on Company’s Pipeline of Non-opioid Analgesic Programs October 2020 Type C meeting planned with the FDA for NTM-006, an oral new chemical entity with a novel mechanism of action targeting neuropathic pain Based on recent FDA...
by admin | Jun 7, 2020 | Press Releases
PALO ALTO, Calif., June 5, 2020 – Neumentum, Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, has posted a presentation for digital viewing for the BIO...
by Sky Striar | Oct 10, 2019 | Press Releases
Agreement significantly expands Neumentum’s pipeline of investigational pain therapies aimed at addressing the growing need for innovative analgesics PALO ALTO, Calif., October 10, 2019 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain...
by Sky Striar | Sep 5, 2019 | Press Releases
Neumentum’s poster presentations #39, #40, #41 and #42 from PAINWeek are now available to view. – Results Support What Has the Potential To Be the First-Ever Non-Steroidal Anti-Inflammatory (NSAID) Approved for Continuous Infusion – Results Confirm...
